Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells

Clinical and Experimental Immunology

Volumn 104, Issue 3, 1996, Pages 501-508

  Matsuoka, N ^b   Eguchi, K ^b   Kawakami, A ^b   Tsuboi, M ^b   Kawabe, Y ^b   Aoyagi, T ^a   Nagataki, S ^b  

^a Ureshino Medical Center   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Adhesion molecule; Clarithromycin; Cytokine; Synoviocyte

Indexed keywords

CLARITHROMYCIN; CYTOKINE; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; TUBERCULIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE;

EID: 0030063950     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.46752.x     Document Type: Article

References (40)

1. Matsubara T, Ziff M. Basement membrane thickening of postcapillary venules and capillaries in rheumatoid synovium. Arthritis Rheum 1987; 30:18-30.
2. Hale LP, Martin ME, Nunley JA, Springer TA, Singer KH, Haynes BF. Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis Rheum 1989; 32:22-30.
3. Miyasaka N, Sato K, Goto M, Sasano M, Natsuyama M, Inoue K, Nishioka K. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction. Arthritis Rheum 1988; 31:480-6.
4. Nakao H, Eguchi K, Kawakami A et al. Phenotypic characterisation of lymphocytes infiltrating synovial tissue from patients with rheumatoid arthritis. J Rheumatol 1990; 17:142-8.
5. Reme T, Portier M, Frayssinoux F, Combe B, Miossec P, Favier F, Sany J. T cell receptor expression and activation of synovial lymphocyte subsets in patients with rheumatoid arthritis. Phenotyping of multiple synovial sites. Arthritis Rheum 1990; 33:485-92.
6. Matsuoka N, Eguchi K, Kawakami A et al. Phenotypic characteristics of T cells interacted with synovial cells. J Rheumatol. 1991; 18:1137-42.
7. Deleuran BW, Chu CQ, Field M, Brennan FM, Katsiki P, Feldmann M, Maini RN. Localization of interleukin-1a, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992; 31:801-9.
8. Farahat MN, Yanni G, Poston R, Panai GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993; 52:870-5.
9. Morimoto S, Takahashi Y, Watanabe Y, Omura S. Chemical modification of erythromycins. 1. Synthesis and antibacterial activity of 6-O-methyl-erythromycins. A J Antibiot 1984; 37:187-9.
10. Takeda H, Miura H, Kawahira M, Kobayashi H, Otomo S, Nakaike S. Long-term administration study of TE-031 (A-56268) in treatment of diffuse panbronchiolitis. J Jpn Assoc Infect Dis 1989; 63:71-8.
11. Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exptl Clin Res 1989; 15:527-33.
12. Arnett FC, Edwrthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
13. Wernick RM, Lipsky PE, Marban-Arcos E, Maliakkal JJ, Edelbaum D, Ziff M. IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures. Arthritis Rheum 1985; 28:742-52.
14. Matsunaga M, Eguchi K, Fukuda T et al. Class II major histocompatibility antigen expression and cellular interactions in thyroid gland of Graves' disease. J Clin Endocrinol Metab 1986; 62:723-8.
15. Mikasa K, Sawaki M, Kita E et al. Long-term chemotherapy using erythromycin for chronic lower airway infection: effectiveness of clarithromycin in erythromycin ineffective case. J Jpn Assoc Infect Dis 1992; 66:1097-104.
16. Danis VA, Kulesz AJ, Nelson DS, Brooks PM. The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interieukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis. Clin Exp Immunol 1990; 79:335-40.
17. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33:305-14.
18. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38:151-60.
19. Kawakami A, Eguchi K, Ueki Y et al. Effects of lobenzarit disodium on human endothelial cells: lobenzarit disodium inhibits proliferative response, HLA-DR antigen expression, and T cell adherence toward endothelial cells. Arthritis Rheum 1991; 34:296-303.
20. Newman PM, To SS, Robinson BG, Hyland VJ, Schriebet L. Effect of gold sodium thiomalate and its thiomalate component on the in vitro expression of endothelial cell adhesion molecules. J Clin Invest 1994; 94:1864-71.
21. van Dinther-Janssen ACHM, Kraal G, van Soesbergen RM, Scheper RJ, Meijer CJLM: Immunohistological and functional analysis of adhesion molecule expression in the rheumatoid synovial lining layer. Implication for synovial lining cell destruction. J Rheumatol 1994; 21:1998-2004.
22. Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, Coblyn JS. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31:167-75.
23. Hirohata S, Lipsky PE. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum 1994; 37:942-50.
24. Hirata S, Matsubara T, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989; 32:1065-73.
25. Hashimoto K, Whitehurst CE, Lipsky PE. Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin. J Rheumatol 1994; 21:1020-6.
26. Suwa T, Yoshida H, Kohno Y, Yoshitomi H, Ohta K. Metabolic fate of TE-031 (A-56268) (III). Chemotherapy 1988; 36:213-26.
27. Firestein GS, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. Arthritis Rheum 1995; 38:151-60.
28. Sims JE, March CJ, Cosman D et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988; 241:585-9.
29. Aguet M, Dembic Z, Merlin G. Molecular cloning and expression of the human interferon-γ receptor. Cell 1988; 55:273-80.
30. Marui N, Offermann MK, Swerlick R et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92:1866-74.
31. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Thierfelder WE, Kreider B, Silvennoinen O. Signaling by the cytokine receptor superfamily: JAKs and STATs. TIBS 1994; 19:222-7.
32. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFN-s and other extracellular signaling proteins. Science 1994; 264:1415-21.
33. Stylianou E, O'Neill LA, Rawlinson L, Edbrooke MR, Woo P, Saklatvala J: Interleukin 1 induces NF-kB through its type I but not its type II receptor in lymphocytes. J Biol Chem 1992; 267:15836-41.
34. Marquardt B, Frith D, Stabel S. Signalling from TPA to MAP kinase requires protein kinase C, raf and MEK: reconstitution of the signalling pathway in vetro. Oncogene 1994; 9:3213-8.
35. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: anautoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20,
36. Katsikis PD, Chu CQ, Brennan FM, Maini, RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994; 179:1517-27.
37. Phillips CA, Cera PJ, Mangan TF, Newman ED. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992; 19:229-33.
38. Jacobs JW, Van der Weide FR, Kruijsen MW. Fatal cholestatic hepatitis caused by D-penicillamine. Brit J Rheumatol 1994; 33:770-3.
39. Craft JC, Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Ped Inf Dis J 1993; 12:s142-147.
40. Guay DR, Patterson DR, Seipman N, Craft JC. Overview of the tulerability profile of clarithromycin in preclinical and clinical trials. Drug Safety 1993; 8:150-64.